Trial Outcomes & Findings for Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma (NCT NCT03030261)

Last Updated: 2024-12-18

Results Overview

-Event-free survival (EFS) will be defined as time from ASCT to disease progression, relapse, or death, whichever occurs first. Patients who are removed from study therapy prior to any of these events occurring will be censored at the time of initiation of subsequent anti-myeloma treatment.

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

PHASE2

Target enrollment

25 participants

Primary outcome timeframe

1 year

Results posted on

2024-12-18

Participant Flow

Participant milestones

Participant milestones
Measure	Elotuzumab + Pomalidomide + Dexamethasone * Patients will receive 2-6 cycles of salvage/induction per standard of care. After protocol version 02/13/2020, patients may have already received their induction therapy prior to enrolling in the study. * Following induction, patients will undergo standard of care ASCT melphalan conditioning (ASCT). Administration of melphalan and the second ASCT will be done as part of routine care and procedures are not dictated by this protocol. * Continuation therapy with Elo-Pom-Dex will begin between Days 80 and 120 following the second ASCT: * 10 mg/kg of elotuzumab on Days 1 and 15 for Cycles 1-6 followed by 20 mg/kg on Day 1 for Cycles 7+ * 2 mg pomalidomide daily on Days 1-21 of all cycles * 40 mg dexamethasone on Days 1 and 15 of all cycles for Cycles 1-6 followed by 40 mg on Day 1 for Cycles 7+ * Continuation therapy may continue until relapse or progression.
Overall Study STARTED	25
Overall Study COMPLETED	20
Overall Study NOT COMPLETED	5

Reasons for withdrawal

Reasons for withdrawal
Measure	Elotuzumab + Pomalidomide + Dexamethasone * Patients will receive 2-6 cycles of salvage/induction per standard of care. After protocol version 02/13/2020, patients may have already received their induction therapy prior to enrolling in the study. * Following induction, patients will undergo standard of care ASCT melphalan conditioning (ASCT). Administration of melphalan and the second ASCT will be done as part of routine care and procedures are not dictated by this protocol. * Continuation therapy with Elo-Pom-Dex will begin between Days 80 and 120 following the second ASCT: * 10 mg/kg of elotuzumab on Days 1 and 15 for Cycles 1-6 followed by 20 mg/kg on Day 1 for Cycles 7+ * 2 mg pomalidomide daily on Days 1-21 of all cycles * 40 mg dexamethasone on Days 1 and 15 of all cycles for Cycles 1-6 followed by 40 mg on Day 1 for Cycles 7+ * Continuation therapy may continue until relapse or progression.
Overall Study Still receiving continuation therapy	5

Baseline Characteristics

Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Elotuzumab + Pomalidomide + Dexamethasone n=25 Participants * Patients will receive 2-6 cycles of salvage/induction per standard of care. After protocol version 02/13/2020, patients may have already received their induction therapy prior to enrolling in the study. * Following induction, patients will undergo standard of care ASCT melphalan conditioning (ASCT). Administration of melphalan and the second ASCT will be done as part of routine care and procedures are not dictated by this protocol. * Continuation therapy with Elo-Pom-Dex will begin between Days 80 and 120 following the second ASCT: * 10 mg/kg of elotuzumab on Days 1 and 15 for Cycles 1-6 followed by 20 mg/kg on Day 1 for Cycles 7+ * 2 mg pomalidomide daily on Days 1-21 of all cycles * 40 mg dexamethasone on Days 1 and 15 of all cycles for Cycles 1-6 followed by 40 mg on Day 1 for Cycles 7+ * Continuation therapy may continue until relapse or progression.
Age, Continuous	62 years n=5 Participants
Sex: Female, Male Female	14 Participants n=5 Participants
Sex: Female, Male Male	11 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	25 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants
Race (NIH/OMB) Asian	1 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	4 Participants n=5 Participants
Race (NIH/OMB) White	20 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants
Region of Enrollment Canada	9 participants n=5 Participants
Region of Enrollment United States	16 participants n=5 Participants

PRIMARY outcome

Timeframe: 1 year

Population: Only 18 patients were evaluable for this outcome measure. 6 patients did not have ASCT and 1 patient had ASCT but did not start continuation treatment.

Outcome measures

Outcome measures
Measure	Elotuzumab + Pomalidomide + Dexamethasone n=18 Participants * Patients will receive 2-6 cycles of salvage/induction per standard of care. After protocol version 02/13/2020, patients may have already received their induction therapy prior to enrolling in the study. * Following induction, patients will undergo standard of care ASCT melphalan conditioning (ASCT). Administration of melphalan and the second ASCT will be done as part of routine care and procedures are not dictated by this protocol. * Continuation therapy with Elo-Pom-Dex will begin between Days 80 and 120 following the second ASCT: * 10 mg/kg of elotuzumab on Days 1 and 15 for Cycles 1-6 followed by 20 mg/kg on Day 1 for Cycles 7+ * 2 mg pomalidomide daily on Days 1-21 of all cycles * 40 mg dexamethasone on Days 1 and 15 of all cycles for Cycles 1-6 followed by 40 mg on Day 1 for Cycles 7+ * Continuation therapy may continue until relapse or progression.
Event-free Survival (EFS) Rate	13 Participants

SECONDARY outcome

Timeframe: 1 year

Population: Only 18 patients were evaluable for this outcome measure. 6 patients did not have ASCT and 1 patient had ASCT but did not start continuation treatment.

-Overall response rate (ORR) will be defined as the proportion of evaluable patients meeting the criteria for partial response (PR), very good partial response (VGPR), complete response (CR), or stringent complete response (sCR).

Outcome measures

Outcome measures
Measure	Elotuzumab + Pomalidomide + Dexamethasone n=18 Participants * Patients will receive 2-6 cycles of salvage/induction per standard of care. After protocol version 02/13/2020, patients may have already received their induction therapy prior to enrolling in the study. * Following induction, patients will undergo standard of care ASCT melphalan conditioning (ASCT). Administration of melphalan and the second ASCT will be done as part of routine care and procedures are not dictated by this protocol. * Continuation therapy with Elo-Pom-Dex will begin between Days 80 and 120 following the second ASCT: * 10 mg/kg of elotuzumab on Days 1 and 15 for Cycles 1-6 followed by 20 mg/kg on Day 1 for Cycles 7+ * 2 mg pomalidomide daily on Days 1-21 of all cycles * 40 mg dexamethasone on Days 1 and 15 of all cycles for Cycles 1-6 followed by 40 mg on Day 1 for Cycles 7+ * Continuation therapy may continue until relapse or progression.
Overall Response Rate (ORR)	18 Participants

SECONDARY outcome

Timeframe: 1 year

Population: Only 18 patients were evaluable for this outcome measure. 6 patients did not have ASCT and 1 patient had ASCT but did not start continuation treatment.

* Complete response rate (CRR) will be defined as the proportion of evaluable patients meeting the criteria complete (CR) or stringent complete response (sCR) * Stringent complete response (sCR) requires all of the following: * CR as defined below * Normal free light chain ratio (0.26-1.65) * Absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence * Complete response (CR) requires all of the following: * Disappearance of monoclonal protein by both protein electrophoresis and immunofixation studies from the blood and urine * If serum and urine monoclonal protein are unmeasurable, Normal free light chain ratio (0.26-1.65) * \<5% plasma cells in the bone marrow * Disappearance of soft tissue plasmacytoma * Patients who do not meet the definition of CR based solely on residual monoclonal protein on serum electrophoresis and/or immunofixation, but are MRD-negative as described above, will also be considered CR.

Outcome measures

Outcome measures
Measure	Elotuzumab + Pomalidomide + Dexamethasone n=18 Participants * Patients will receive 2-6 cycles of salvage/induction per standard of care. After protocol version 02/13/2020, patients may have already received their induction therapy prior to enrolling in the study. * Following induction, patients will undergo standard of care ASCT melphalan conditioning (ASCT). Administration of melphalan and the second ASCT will be done as part of routine care and procedures are not dictated by this protocol. * Continuation therapy with Elo-Pom-Dex will begin between Days 80 and 120 following the second ASCT: * 10 mg/kg of elotuzumab on Days 1 and 15 for Cycles 1-6 followed by 20 mg/kg on Day 1 for Cycles 7+ * 2 mg pomalidomide daily on Days 1-21 of all cycles * 40 mg dexamethasone on Days 1 and 15 of all cycles for Cycles 1-6 followed by 40 mg on Day 1 for Cycles 7+ * Continuation therapy may continue until relapse or progression.
Complete Response Rate (CRR)	12 Participants

SECONDARY outcome

Timeframe: Up to 5 years post completion of treatment

-Progression-free survival (PFS) will be defined as time from ASCT to disease progression or relapse. Any patient who expires or withdraws prior to disease progression or relapse will be censored at last follow-up. Patients who are removed from study therapy prior to progression or relapse will be censored at the time of initiation of subsequent anti-myeloma treatment.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 5 years post completion of treatment

-Overall survival (OS) will be defined as time from ASCT to death due to any causes. Patients who are alive at the time of data analyses will be censored on the last known alive date. Patients who are removed from study therapy prior death will be censored at the time of initiation of subsequent anti-myeloma treatment.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 30 days following completion of treatment (estimated to be 106 weeks)

-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.

Outcome measures

Outcome data not reported

Adverse Events

Induction Therapy On Study

Serious events: 6 serious events

Other events: 16 other events

Deaths: 0 deaths

Continuation

Serious events: 7 serious events

Other events: 18 other events

Deaths: 0 deaths

Follow-up

Serious events: 0 serious events

Other events: 0 other events

Deaths: 8 deaths

Serious adverse events

Other adverse events

Additional Information

Ravi Vij, M.D.

Washington University School of Medicine

Phone: 314-454-8323

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Serious adverse events
Measure	Induction Therapy On Study n=16 participants at risk -Patients will receive 2-6 cycles of salvage/induction per standard of care. After protocol version 02/13/2020, patients may have already received their induction therapy prior to enrolling in the study.	Continuation n=18 participants at risk * Continuation therapy with Elo-Pom-Dex will begin between Days 80 and 120 following the second ASCT: * 10 mg/kg of elotuzumab on Days 1 and 15 for Cycles 1-6 followed by 20 mg/kg on Day 1 for Cycles 7+ * 2 mg pomalidomide daily on Days 1-21 of all cycles * 40 mg dexamethasone on Days 1 and 15 of all cycles for Cycles 1-6 followed by 40 mg on Day 1 for Cycles 7+ * Continuation therapy may continue until relapse or progression.	Follow-up -Participants will be followed annually for up to 5 years after removal from study or until death, whichever occurs first.
Cardiac disorders Heart failure	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	0.00% 0/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Cardiac disorders Myocardial infarction	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Gastrointestinal disorders Abdominal pain	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Gastrointestinal disorders Diarrhea	6.2% 1/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Fatigue	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	0.00% 0/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Fever	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	0.00% 0/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Infusion related reaction	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Infections and infestations E. coli sepsis	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Infections and infestations Lung infection	12.5% 2/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	11.1% 2/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Infections and infestations Rhinovirus	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Infections and infestations Sepsis	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Infections and infestations Staph lugdunensis right toe	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Infections and infestations Upper respiratory infection	6.2% 1/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	16.7% 3/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Infections and infestations Urinary tract infection	12.5% 2/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	0.00% 0/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Renal and urinary disorders Acute kidney injury (multiple myeloma progression)	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Reproductive system and breast disorders Pelvic pain	6.2% 1/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	0.00% 0/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.

Other adverse events
Measure	Induction Therapy On Study n=16 participants at risk -Patients will receive 2-6 cycles of salvage/induction per standard of care. After protocol version 02/13/2020, patients may have already received their induction therapy prior to enrolling in the study.	Continuation n=18 participants at risk * Continuation therapy with Elo-Pom-Dex will begin between Days 80 and 120 following the second ASCT: * 10 mg/kg of elotuzumab on Days 1 and 15 for Cycles 1-6 followed by 20 mg/kg on Day 1 for Cycles 7+ * 2 mg pomalidomide daily on Days 1-21 of all cycles * 40 mg dexamethasone on Days 1 and 15 of all cycles for Cycles 1-6 followed by 40 mg on Day 1 for Cycles 7+ * Continuation therapy may continue until relapse or progression.	Follow-up -Participants will be followed annually for up to 5 years after removal from study or until death, whichever occurs first.
Blood and lymphatic system disorders Anemia	50.0% 8/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	16.7% 3/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Cardiac disorders Atrial fibrillation	6.2% 1/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	11.1% 2/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Cardiac disorders Chest pain	12.5% 2/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Cardiac disorders Chest tightness	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	0.00% 0/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Cardiac disorders Palpitations	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	16.7% 3/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Cardiac disorders Sinus bradycardia	6.2% 1/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	0.00% 0/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Cardiac disorders Sinus tachycardia	6.2% 1/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Ear and labyrinth disorders Earwax buildup	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Ear and labyrinth disorders Tinnitus	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Eye disorders Blurred vision	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Eye disorders Double vision	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Eye disorders Dry eye	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Eye disorders Glaucoma	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Eye disorders Haze on left eye	6.2% 1/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	0.00% 0/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Gastrointestinal disorders Abdominal distension	6.2% 1/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	0.00% 0/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Gastrointestinal disorders Abdominal pain	18.8% 3/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	11.1% 2/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Gastrointestinal disorders Constipation	25.0% 4/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	38.9% 7/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Gastrointestinal disorders Diarrhea	31.2% 5/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	55.6% 10/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Gastrointestinal disorders Dry mouth	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	11.1% 2/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Gastrointestinal disorders Gastroenteritis	6.2% 1/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	0.00% 0/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Gastrointestinal disorders Hemorrhoids	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Gastrointestinal disorders Mucositis oral	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Gastrointestinal disorders Nausea	31.2% 5/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	33.3% 6/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Gastrointestinal disorders Oral pain	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Gastrointestinal disorders Toothache	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
Gastrointestinal disorders Vomiting	12.5% 2/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	16.7% 3/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Chills	12.5% 2/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	0.00% 0/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Edema limbs	18.8% 3/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	22.2% 4/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Fatigue	62.5% 10/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	44.4% 8/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Fever	31.2% 5/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	16.7% 3/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Flu like symptoms	6.2% 1/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	11.1% 2/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Flushing	6.2% 1/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	0.00% 0/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders IV pain	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Infusion related reaction	12.5% 2/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Localized edema	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Malaise	6.2% 1/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Neck edema	0.00% 0/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	5.6% 1/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Non-cardiac chest pain	12.5% 2/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	16.7% 3/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.
General disorders Pain	18.8% 3/16 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	0.00% 0/18 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.	— 0/0 • -Following induction and continuation therapy, AEs & all-cause mortality are collected from start of treatment through 30 days after treatment completion or the start of next anti-myeloma therapy. AEs were followed for median of 434 days, full range 83-1424 days. -During the follow-up phase, all-cause mortality data are collected through 5 years after treatment completion, up to 10 years. All-cause mortality were followed for median of 884 days, full range 187-1948 days. The follow-up group is to show all-cause mortality only. Induction On Study group will show AEs and SAEs that occurred during that treatment time period and 30 days after that treatment time period if they stopped treatment in that time period. The Continuation group will show AEs and SAE that occurred during that treatment time period and for 30 days after that treatment time period if they stopped treatment in that time period.